Your shopping cart is currently empty

EGFR-IN-163 (Compound 13) is a competitive inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 0.079 μM and selective inhibition on HER-2. It induces apoptosis in tumor cells and causes cell cycle arrest at the G₂/M phase. EGFR-IN-163 shows promise for investigating estrogen receptor-positive (ER+) breast cancer.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | EGFR-IN-163 (Compound 13) is a competitive inhibitor of the epidermal growth factor receptor (EGFR) with an IC50 of 0.079 μM and selective inhibition on HER-2. It induces apoptosis in tumor cells and causes cell cycle arrest at the G₂/M phase. EGFR-IN-163 shows promise for investigating estrogen receptor-positive (ER+) breast cancer. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.